Progressive myoclonus epilepsies (PMEs) are disorders characterized by myoclonic and generalized seizures with progressive neurological deterioration. While several genetic causes for PMEs have been identified, the underlying causes remain unknown for a substantial portion of cases. Here we describe several affected individuals from a large, consanguineous family presenting with a novel PME in which symptoms begin in adolescence and result in death by early adulthood. Whole exome analyses revealed that affected individuals have a homozygous variant in GPR37L1 (c.1047G N T [Lys349Asn] ), an orphan G protein-coupled receptor (GPCR) expressed predominantly in the brain. In vitro studies demonstrated that the K349N substitution in Gpr37L1 did not grossly alter receptor expression, surface trafficking or constitutive signaling in transfected cells. However, in vivo studies revealed that a complete loss of Gpr37L1 function in mice results in increased seizure susceptibility. Mice lacking the related receptor Gpr37 also exhibited an increase in seizure susceptibility, while genetic deletion of both receptors resulted in an even more dramatic increase in vulnerability to seizures. These findings provide evidence linking GPR37L1 and GPR37 to seizure etiology and demonstrate an association between a GPR37L1 variant and a novel progressive myoclonus epilepsy.
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Introduction
Several forms of epilepsy are highly heritable, but underlying mutations have been identified in only a small fraction of epilepsy patients (Berg et al., 2010; EPICURE Consortium, 2012; Epi4K Consortium, 2016; Franceschetti et al., 2014; Heinzen et al., 2012; Kasperaviciute et al., 2010; Mulley and Mefford, 2011) . The identification of new epilepsy-associated gene variants is important as it can potentially lead to novel targets and approaches for treating epilepsy. Progressive myoclonus epilepsies (PMEs) are rare epilepsy syndromes that result in myoclonic and generalized seizures with progressive neurological deterioration. PMEs typically present in late childhood and/or adolescence. They are among the most devastating forms of epilepsy as they are often associated with debilitating disease progression and poor outcomes. Most PMEs are inherited in an autosomal recessive (AR) manner (Shahwan et al., 2005) . For example, Unverricht-Lundborg disease (MIM 254800), the most common PME, is caused by AR mutations in CSTB (MIM 601145) (Lehesjoki and Gardiner, 2012; Pennacchio et al., 1996; Shahwan et al., 2005) , the gene encoding cystatin B. In contrast, Lafora disease (MIM 254780), another form of PME, is caused by AR mutations in EPM2A (MIM 607566) and NHLRC1 (MIM 608072), the genes encoding laforin and malin, respectively (Chan et al., 2003; Franceschetti et al., 2014; Minassian et al., 1998) . Thus, although the genetic bases for several PMEs are known, additional genes remain to be identified for a substantial number of other cases (Franceschetti et al., 2014) .
Exome and genome sequencing are powerful tools that have dramatically increased disease gene discovery (Boycott et al., 2013) . Here we present a large family of Iraqi descent with five children affected with PME. Previous clinical testing was negative and the family was therefore enrolled in a research exome study. A novel homozygous variant, c.1047G N T [Lys349Asn], of unknown significance was identified in GPR37L1, an orphan G protein-coupled receptor (GPCR) expressed predominantly in the brain (Cahoy et al., 2008; Leng et al., 1999; Valdenaire et al., 1998) . GPR37L1 and its closest relative, GPR37, are class A, rhodopsin-like family members. These receptors share their strongest sequence similarity to the endothelin and bombesin receptors and other 
Contents lists available at ScienceDirect
Neurobiology of Disease j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y n b d i
